MedTrace Logo

A Study to Evaluate the Efficacy of ELAPR in Women With Striae Distensae Alba

NCT02510768 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2018-07-02

No results posted yet for this study

Summary

The study is designed to evaluate the efficacy of two formulations of a cross-linked tropoelastin matrix given the product codes ELAPR002f and ELAPR002g (collectively referred to as ELAPR or ELAPR002) for the treatment of Striae Distensae (SD) alba when administered as intradermal implants.

Conditions

  • Striae Distensae

Interventions

DEVICE

ELAPR002f

Intradermal implant

DEVICE

ELAPR002g

Intradermal implant

DEVICE

Saline

Intradermal implant

Sponsors & Collaborators

  • Elastagen Pty Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-04-16
Primary Completion
2017-10-03
Completion
2018-03-06

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02510768 on ClinicalTrials.gov